SpringWorks Therapeutics receives positive CHMP Opinion for mirdametinib (Ezmekly) for the treatment of adult and pediatric patients with NF1-PN
SpringWorks Therapeutic Inc. announced the EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for… read more.
